Use of traditional Chinese medicine composition combined with probiotics in preparation of a drug for treating ulcerative colitis combined with fatty liver

By combining traditional Chinese medicine composition with probiotics Muribaculum intestinale, the problem of regulating intestinal flora and liver pathology in existing technologies has been solved, achieving effective treatment for ulcerative colitis complicated with fatty liver and restoring the health of the intestines and liver.

CN122398901APending Publication Date: 2026-07-17THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU UNIV OF CHINESE MEDICINE

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU UNIV OF CHINESE MEDICINE
Filing Date
2026-05-07
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Current treatments for ulcerative colitis complicated with fatty liver are unable to effectively regulate the gut microbiota, fundamentally repair the intestinal mucosa, regulate the balance of the gut microbiota, or break the vicious cycle of the gut-liver axis, leading to increased treatment difficulty and poor prognosis.

Method used

The combined application of traditional Chinese medicine composition and probiotic Muribaculum intestinale achieves synergistic effects of regulating gut flora, clearing damp heat, promoting blood circulation, and repairing mucous membranes. The traditional Chinese medicine composition includes Agrimonia pilosa, Sanguisorba officinalis, Aucklandia lappa, Atractylodes lancea, Coptis chinensis, Hirudo medicinalis, Paeonia lactiflora, Polygonum cuspidatum, and Ligusticum striatum. The probiotic Muribaculum intestinale supplements beneficial bacteria in the intestines, inhibits the growth of pathogenic bacteria, regulates the balance of gut flora, and enhances the anti-inflammatory and mucosal repair effects of the traditional Chinese medicine.

Benefits of technology

It significantly improves the symptoms of ulcerative colitis and fatty liver, restores the pathological damage to the intestinal mucosa and liver, breaks the vicious cycle of 'bacteria-inflammation-damage', and enhances the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

本发明属于医药技术领域,具体涉及中药组合物联合益生菌在制备治疗溃疡性结肠炎合并脂肪肝药物中的应用,其中,中药组合物以重量份计包括以下原料:仙鹤草10‑30份、地榆9‑15份、木香6‑10份、苍术6‑15份、黄连3‑10份、水蛭1‑5份、赤芍6‑15份、火炭母9‑30份、救必应9‑30份;益生菌为Muribaculum intestinale。本发明提供的中药组合物联合益生菌通过“调菌群、清湿热、活气血、修黏膜”的协同作用,实现对溃疡性结肠炎合并脂肪肝的有效治疗。
Need to check novelty before this filing date? Find Prior Art